EGFR and non-small cell lung carcinoma: Preclinical studies have suggested that the immune microenvironment can influence the effects of targeted therapy and may serve as one of the mechanisms of resistance to small molecule inhibitors (6–8), but the clinical significance of this interaction in EGFR-mutant NSCLC has not been well-verified.